Page last updated: 2024-08-25

adriamycinol and Recrudescence

adriamycinol has been researched along with Recrudescence in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brown, AM; Bryant, J; Dakhil, SR; Davidson, NE; Fehrenbacher, L; Geyer, CE; Ingle, JN; Jenkins, RB; Kaufman, PA; Klein, PM; Kutteh, LA; Lingle, WL; Mamounas, EP; Martino, S; Paik, S; Perez, EA; Pisansky, TM; Romond, EH; Suman, VJ; Swain, SM; Tan-Chiu, E; Visscher, DW; Vogel, VG; Wolmark, N; Yothers, G	1

Trials

1 trial(s) available for adriamycinol and Recrudescence

Article	Year
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England journal of medicine, 2005, Oct-20, Volume: 353, Issue:16 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Diseases; Humans; Mastectomy; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Recurrence; Survival Analysis; Trastuzumab	2005

Article

Year

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

The New England journal of medicine, 2005, Oct-20, Volume: 353, Issue:16

Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Diseases; Humans; Mastectomy; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Recurrence; Survival Analysis; Trastuzumab

2005